| BGE-102 | BioAge Labs | Cardiovascular Risk and Metabolic Dysfunction | Phase 1 | Active |
| APJ Program | BioAge Labs | Obesity | Preclinical | Active |
| Tagrisso (osimertinib) | AstraZeneca | EGFR-mutated lung cancer | Approved | Commercial |
| Imfinzi (durvalumab) | AstraZeneca | Various cancers | Approved | Commercial |
| Lynparza (olaparib) | AstraZeneca | BRCA-mutated cancers | Approved | Commercial |
| Calquence (acalabrutinib) | AstraZeneca | Blood cancers | Approved | Commercial |
| Farxiga (dapagliflozin) | AstraZeneca | Diabetes/Heart failure/CKD | Approved | Commercial |
| Brilinta (ticagrelor) | AstraZeneca | Cardiovascular disease | Approved | Commercial |
| Symbicort | AstraZeneca | Asthma/COPD | Approved | Commercial |
| Breztri | AstraZeneca | COPD | Approved | Commercial |
| Forxiga | AstraZeneca | Type 2 diabetes | Approved | Commercial |
| Crestor (rosuvastatin) | AstraZeneca | High cholesterol | Approved | Commercial |
| Cosentyxยฎ | Novartis | Pediatric Hidradenitis Suppurativa (12+) | Approved | FDA Approved March 2026 |
| Pan-mutant-selective PI3Kฮฑ inhibitor | Novartis | Breast Cancer | Acquisition | Under acquisition |
| Mitoxantrone Liposome | CSPC Pharmaceutical Group Limited | Various Cancers | Phase 3 | Active |
| Doxorubicin Liposome | CSPC Pharmaceutical Group Limited | Ovarian Cancer | Phase 3 | Active |
| Alemtuzumab Biosimilar | CSPC Pharmaceutical Group Limited | Hematologic Malignancies | Phase 3 | Active |
| CSPC-DM02 | CSPC Pharmaceutical Group Limited | Solid Tumors | Phase 2 | Active |
| NBP (Butylphthalide) | CSPC Pharmaceutical Group Limited | Stroke | Commercial | Marketed |
| Caffeine Citrate | CSPC Pharmaceutical Group Limited | Neonatal Apnea | Commercial | Marketed |
| Vitamin D Analogs | CSPC Pharmaceutical Group Limited | Chronic Kidney Disease | Commercial | Marketed |
| Resmetirom | Madrigal Pharmaceuticals | MASH with moderate to advanced fibrosis (F2-F3) | Approved | Commercial |
| Ervogastat combination | Madrigal Pharmaceuticals | MASH | Phase 2 | Planned 2027 |
| MGL-2086 | Madrigal Pharmaceuticals | Undisclosed | Phase 1 | Expected 2Q26 |
| Cardiovascular Portfolio | Shenzhen Salubris Pharmaceuticals | Hypertension and Heart Disease | Commercial | Active |
| Respiratory Products | Shenzhen Salubris Pharmaceuticals | Respiratory Disorders | Commercial | Active |
| Metabolic Disease Products | Shenzhen Salubris Pharmaceuticals | Diabetes and Metabolic Disorders | Commercial | Active |
| Generic Drug Portfolio | Shenzhen Salubris Pharmaceuticals | Various Therapeutic Areas | Commercial | Active |
| Medical Device Products | Shenzhen Salubris Pharmaceuticals | Diagnostic and Therapeutic Applications | Commercial | Active |
| Rusfertide (PTG-300) | Protagonist Therapeutics | Polycythemia Vera | Phase 3 | VERIFY study completed |
| Icotrokinra (JNJ-2113) | Protagonist Therapeutics | Moderate-to-Severe Psoriasis | Phase 3 | Multiple Phase 3 studies completed |
| PN-881 | Protagonist Therapeutics | Psoriasis, Psoriatic Arthritis, Hidradenitis Suppurativa, Spondyloarthritis | Phase 1 | Initiated Q4 2025 |
| PN-477sc | Protagonist Therapeutics | Obesity & Associated Co-Morbidities | IND-Enabling | Phase 1 initiation Mid 2026 |
| PN-477oral | Protagonist Therapeutics | Obesity & Associated Co-Morbidities | IND-Enabling | Phase 1 initiation 2H 2026 |
| Oral Hepcidin | Protagonist Therapeutics | Polycythemia Vera, Hereditary Hemochromatosis | Pre-clinical | Development candidate Q4 2025 |
| Tinlarebant (LBS-008) | Belite Bio | Geographic Atrophy (Dry AMD) | Phase 3 | Active |
| LBS-009 | Belite Bio | Non-Fatty Liver Disease | Preclinical | Active |
| Leclaza (Lazertinib) | Yuhan | EGFR T790M-mutated Non-Small Cell Lung Cancer (NSCLC) | Approved | Commercial/Phase 3 Global |
| Jentadueto (Linagliptin/Metformin) | Yuhan | Type 2 Diabetes | Approved | Commercial |
| Nesina (Alogliptin) | Yuhan | Type 2 Diabetes | Approved | Commercial |
| YH25448 (Gumarontinib) | Yuhan | EGFR Exon20 Insertion+ NSCLC | Phase 3 | Active |
| YH32367 | Yuhan | HER2-positive Solid Tumors | Phase 1/2 | Active |
| YH29407 | Yuhan | Multiple Myeloma | Phase 1 | Active |
| YH003 | Yuhan | Solid Tumors (e.g., Pancreatic Cancer) | Phase 2 | Active |
| YH001 | Yuhan | Solid Tumors | Phase 2 | Active |
| YH14618 | Yuhan | Metabolic Dysfunction-Associated Steatohepatitis (MASH) | Phase 1 | Active |
| YH25724 | Yuhan | Fibrotic Diseases | Preclinical/Phase 1 | In development |
| Chemical Generics Portfolio | China Resources Pharmaceutical Group | Various (Cardiovascular, CNS, Anti-infective) | Approved | Commercial |
| Traditional Chinese Medicine Portfolio | China Resources Pharmaceutical Group | Various Chronic Diseases & Wellness | Approved | Commercial |
| Biosimilar Candidates | China Resources Pharmaceutical Group | Oncology, Autoimmune Diseases | Phase 3 | Active |